7results about How to "Reduced proliferative capacity" patented technology

The invention discloses application of HOXD1 in diagnosis, prognosis and treatment of liver cancer, and particularly relates to application of a reagent for detecting expression of a biomarker HOXD1 in preparation of a product for diagnosing a liver cancer object. The invention discloses application of a reagent for detecting expression of a biomarker HOXD1 in preparation of a product for prognosis of a liver cancer object. The invention discloses an application of HOXD1 as a target in screening medicines for treating liver cancer. The HOXD1 expression inhibitor is applied to preparation of a medicine for treating liver cancer. Differential expression of the HOXD1 in hepatocellular carcinoma tissues and normal hepatocellular carcinoma tissues is clear through research, high expression of the HOXD1 is closely related to the survival reduction period of clinical hepatocellular carcinoma patients, specific knock-down of the HOXD1 can obviously reduce the proliferation capacity of the hepatocellular carcinoma, and a new diagnosis / prognosis marker and a treatment target are provided for early discovery, early treatment and prognosis of the hepatocellular carcinoma. And a new treatment strategy and direction are provided.

The invention discloses application of a yncJ gene in regulation and control of toxicity of salmonella typhimurium, and belongs to the technical field of biology. According to the invention, the function of the yncJ gene is studied by constructing the yncJ gene deleted strain of salmonella typhimurium, and it is found that after the yncJ gene is deleted, the multiplication capacity of the strain in macrophages is significantly reduced; infected mouse experiments show that the lethal ability of the yncJ gene deleted strain to mice is remarkably reduced. Moreover, the conventional biochemical characteristics and the in-vitro growth speed of the yncJ gene deletion strain are not obviously changed, so that the yncJ gene deletion strain has an application prospect in production of attenuated vaccines for preventing and treating salmonella typhimurium.

The present invention relates to biomedicine, and in particular to LncRNA WARS2-IT1 inhibitors and applications thereof. After knocking down or silencing LncRNA WARS2-IT1 using the LncRNA WARS2-IT1 inhibitor, the proliferation ability, migration ability, and invasion ability of glioma cells are significantly reduced. The LncRNA WARS2-IT1 inhibitor can be used in the preparation of products such as diagnosis and treatment of gliomas and improving the sensitivity of targeted drugs, and has good application prospects.

The invention discloses application of K224 lactic acid modification of HNRNPF as a target spot in preparation of a product for diagnosis and / or treatment of pancreatic cancer, and belongs to the technical field of tumor precision medical products. The embodiment of the invention proves that the lactylation modification level of the K224th site of the HNRNPF protein in pancreatic cancer tissues is obviously higher than that of para-carcinoma tissues, the lactylation modification level of the 224th lysine of the HNRNPF protein is positively related to the progression of pancreatic cancer, and the multiplication capacity of pancreatic cancer cells can be obviously inhibited by constructing the HNRNPF K224R site mutant. On the basis, the reagent for detecting the HNRNPF K224 lactylation level can be used for preparing products for diagnosing and / or treating pancreatic cancer, such as a reagent for detecting or inhibiting the modification and the like. The application provides a novel specific marker and an intervention strategy for early diagnosis and targeted therapy of pancreatic cancer, and has important significance and application value.

This invention relates to the field of plant tissue culture technology, specifically to a culture medium and method for inducing and regenerating tiger nut callus. This invention creatively combines growth regulators (2,4-D, 6-BA, NAA, and ZT) in the culture medium for three different stages of tiger nut callus induction, regeneration, and differentiation, and optimizes the selection of the best explants. This allows each component to fully synergistically enhance its effect at each stage, resulting in high callus induction rate, good growth status, low browning degree, good proliferation effect, and high differentiation rate and differentiation coefficient. Furthermore, no growth regulators are required during rooting induction, resulting in lower costs. This invention lays the foundation for tiger nut gene function research, variety genetic improvement, and germplasm resource optimization.

The invention belongs to the technical field of biological medicines, and particularly relates to application of SIRT5inhibitor 1 in treatment of Philadelphia chromosome positive acute lymphocytic leukemia. The invention proves that the SIRT5inhibitor 1 can be used for specifically inhibiting the expression of the SIRT5 of the Ph + ALL cell; it is found for the first time that the SIRT5inhibitor 1 can weaken the Ph + ALL cell proliferation capacity, the cell cycle is retarded in the G2 / M period, and the apoptosis level is remarkably increased; it is found that the SIRT5inhibitor 1 enables the mitochondrial membrane potential level of the Ph + ALL cells to be obviously reduced, respiratory chain electron leakage is caused, reactive oxygen species (ROS) in the cells is increased, and then cell death is promoted; when the NAC is used for resisting the ROS effect, the effect of the SIRT5inhibitor 1 for causing apoptosis of the Ph + ALL cells is reversed, and it is further proved that the SIRT5inhibitor 1 promotes cell death by increasing the ROS in the Ph + ALL cells. The invention aims to provide a new strategy and method for treating Ph + ALL.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a G-protein-coupled receptor 3 (GPR3) or GPR3 downstream signal molecule XPC as a target spot in preparation of a medicine for treating melanoma. The GPR3 is taken as a target spot, and the expression of the GPR3 is knocked out or knocked down, so that the proliferation ability, migration ability and invasion ability of melanoma cells can be remarkably reduced, the Ki67 level can be remarkably reduced, the Cleved-Caspase3 level can be improved, the sensitivity of tumor cells to ultraviolet rays can be improved, the genomes of the tumor cells are damaged, apoptosis occurs, and the melanoma can be treated; the overexpression of the GPR3 promotes the characteristics of tumor stem cells to cause proliferation and metastasis of the tumor cells, and the expression of XPC and a stemness marker can be inhibited and tumor proliferation can be inhibited by knocking out or knocking down the expression of the GPR3. Therefore, GPR3 or a GPR3 downstream signal molecule XPC is an important target spot for treating melanoma.